3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
23
Carboplatin
22
Capecitabine
18
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
pembrolizumab
14
Cyclophosphamide
12
atezolizumab
9
Epirubicin
9
sacituzumab govitecan
8
Albumin-Bound Paclitaxel
8
eribulin
6
Vinorelbine
6
Drug Therapy
6
Doxorubicin
6
camrelizumab
4
Docetaxel
4
Cisplatin
4
Injections
3
pegfilgrastim
2
olaparib
2
famitinib
2
Filgrastim
2
Everolimus
2
veliparib
1
trilaciclib
1
toripalimab
1
taxane
1
niraparib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn